MRAP2 Polypeptide Immunity-Inducing Agent for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgical, radiation, and chemotherapy, have limited effectiveness in improving outcomes for most cancer types, and there is a lack of effective immunity-inducing agents targeting cancer cells.
Innovation Solution
Development of a novel immunity-inducing agent using a polypeptide derived from the Melanocortin 2 receptor accessory protein 2 (MRAP2), which is expressed in various cancers, to induce immune cells and activate cytotoxic T cells, thereby reducing tumor size and inducing an antitumor effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, radiation, chemotherapy) are used, then cancer cells can be removed or controlled, but treatment outcomes remain unimproved for most cancer types and side effects occur
Solution Approach 1:
The patent introduces MRAP2 polypeptide as an intermediary substance that bridges the gap between conventional treatments and cancer cells. The polypeptide acts as a mediator by inducing immune cells to recognize and attack cancer cells, thereby enhancing treatment effectiveness without directly damaging healthy tissues like conventional therapies do
Solution Approach 2:
The invention enables the patient's own immune system to fight cancer by introducing MRAP2 polypeptide that stimulates endogenous immune cells (cytotoxic T cells, NK cells). This self-service approach allows the body's immune system to naturally identify and eliminate cancer cells, reducing reliance on external aggressive treatments and their associated side effects
2Reliability
If antigen-specific immunotherapy is developed, then cancer antigen recognition by cytotoxic T cells can be improved, but lack of effective immunity-inducing agents limits its application
Solution Approach 1:
The MRAP2 polypeptide serves multiple functions: it acts as an antigen to induce immune responses, stimulates proliferation of immune cells, and enhances activation of cytotoxic T cells. This multi-functionality makes it a versatile immunity-inducing agent that can be applied across different cancer types expressing MRAP2, addressing the lack of available agents
Solution Approach 2:
The patent employs preliminary action by introducing MRAP2 polypeptide before or alongside conventional treatments to pre-activate the immune system. This preliminary immune stimulation ensures that when cancer cells are targeted, the immune system is already primed and ready to respond effectively, overcoming the limitation of insufficient immunity-inducing agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MRAP2 polypeptide induces immune responses, specifically activating cytotoxic T cells to target and reduce cancer tumors, providing a therapeutic and preventive agent for cancers such as leukemia, lymphoma, and other tumor types.
Implementation Method 1
the MRAP2 polypeptide is presented by an antigen-presenting cell and has an ability (also referred to as 'immunity-inducing activity') to activate and proliferate a cytotoxic T cell specific to the polypeptide
Data Source
AI summary
The present invention relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MRAP2 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.